Therefore, considering the connections about IL-1β and fullerol in IDD and ROS respectively, fullerol may be served as a valid biological therapy to treat IDD, further experimental studies need to focus on fullerol to validate these effects. The gene discussed is IL1B; the disease is intervertebral disk degenerative disorder.